

	Moderate Illness (n:62) Mean \pm SD	Severe Illness (n:40) Mean \pm SD	p
Age (year)	56,5 \pm 15,8	55,5 \pm 13,6	0,753
WBC (/ μ L)	9597,7 \pm 4246,6	13769,3 \pm 5799,2	0,001
Lymphocytes (/ μ L)	934,2 \pm 504,5	553,1 \pm 332,1	0,001
Neutrophils (/ μ L)	7829,6 \pm 4076,6	8909,2 \pm 4218,6	0,205
NLR	10,5 \pm 8,1	25,7 \pm 28,4	0,001
AST (U/L)	58,7 \pm 41,7	60,5 \pm 41,6	0,836
ALT (U/L)	71,9 \pm 70,1	80,2 \pm 78,9	0,582
LDH (U/L)	434,2 \pm 139,8	620,9 \pm 201,2	0,001
GGT (U/L)	74,5 \pm 40,4	134,6 \pm 258,3	0,075
ALP (U/L)	98,6 \pm 50,8	103,7 \pm 59,1	0,655
Creatine (mg/dL)	1,1 \pm 0,9	0,9 \pm 1	0,543
Prothrombin time (s)	12,6 \pm 2,3	14,5 \pm 5,4	0,05
CRP (mg/dL)	59,3 \pm 67,2	174,6 \pm 89,9	0,001
Troponin-I (ng/dL)	27,5 \pm 63,3	44,5 \pm 47,3	0,127
PaO ₂ /FiO ₂	270,8 \pm 71,9	174,1 \pm 26,2	0,001
D-Dimer (ng/mL)	1271,5 \pm 1807,2	3374,5 \pm 5246,8	0,005
Ferritin (ng/mL)	633,3 \pm 286,4	1433,3 \pm 305,6	0,001
Fibrinogen (ng/ml)	417,6 \pm 141,9	524,9 \pm 158,1	0,001

Table 1. Comparison of laboratory parameters in hospitalization of patients with moderate to severe COVID-19

WBC: White blood cells, NLR: Neutrophil/lymphocyte ratio, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, LDH: Lactate dehydrogenase, GGT: Gamma glutamyl transferase, ALP: Alkaline phosphatase, SD: Standard deviation, p: Comparison of parameters between groups

Table 2. Comparison of hospitalization suPAR and KIM-1 levels of COVID-19 patients among themselves and with the control group according to the severity of the disease

	Severity of the Illness		Control (mean \pm SD) (n:30)	p*/p**
	Moderate (mean \pm SD) (n:62)	Severe (mean \pm SD) (n:40)		
suPAR (ng/L)	282,4 \pm 264,5	185,9 \pm 124,5	70,3 \pm 33,2	0,034/0,001
KIM-1 (pg/ml)	84,5 \pm 62,3	134,9 \pm 66,5	34,6 \pm 57,4	0,001/0,001

suPAR: soluble urokinase plasminogen activator receptor, KIM-1: Kidney injury molecule-1, SD: Standard deviation, p*: Statistical evaluation of patients among themselves, p**: Statistical evaluation of patient groups with control, p***: Statistical evaluation of patient groups with control group